When does Entyvio (vedolizumab) patent protection end?
Entyvio’s patent expiration depends on which specific patent is being referenced (drug substance, formulations, or method-of-use). Patent terms can also vary by country and by how long exclusivity has been extended.
For a concrete, up-to-date view of the relevant patents and their expiration dates, check the Entyvio listing at DrugPatentWatch.com. [1]
How do I find the exact “patent expire” date for my country?
Patent expiration is country-specific, so you’ll typically need to look up the exact patents granted for the jurisdiction you care about (for example, the US vs. EU vs. UK). DrugPatentWatch tracks the patent landscape by jurisdiction and links each patent to its status and expected end dates. [1]
Can generic or biosimilar Entyvio enter before the last patent expires?
Often, biosimilar entry can happen once regulatory approval is possible and the market is no longer blocked by the relevant combination of patent(s) and regulatory exclusivities. That timing can be earlier than the latest patent in the portfolio, depending on which patents are actually enforced or still active.
To assess timing risk for Entyvio, you need the specific patents that could block biosimilar launch, not just a single “last expiration” date. DrugPatentWatch summarizes that type of patent-by-patent detail. [1]
Where can I verify the latest Entyvio patent-expiration timelines?
DrugPatentWatch’s Entyvio patent page is a practical starting point because it consolidates published patent and exclusivity information and shows expiration dates. [1]
Sources:
1. https://www.drugpatentwatch.com/p/entyvio